RNAZ
TransCode Therapeutics, Inc.
There isn't enough reported data to score RNAZ yet.
RNAZ Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
RNAZ's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
RNAZ PE Valuation
RNAZ has no meaningful PE right now: it lost money over the past year.
RNAZ Forward outlook
There aren't enough analyst estimates for RNAZ to show an outlook.
RNAZ Earnings Per Share
RNAZ lost $1,804.47 per share over the past year, a smaller loss than the year before.
RNAZ Quarterly Revenue
RNAZ Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | -$8.1M | -$5M |
| Q4 2024 | -$3.1M | +$2.5M |
| Q3 2024 | -$3.9M | -$415.1K |
| Q2 2024 | -$2.3M | +$2.1M |
| Q1 2024 | -$3.9M | +$585.4K |
| Q4 2023 | -$5.7M | -$1.6M |
| Q3 2023 | -$3.5M | +$911.6K |
| Q2 2023 | -$4.4M | -$995.6K |
RNAZ has burned cash in almost every quarter: −$22M over the past year, against −$16M the year before.
RNAZ Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -20% | -3.2K shares |
| 1 year | +14862% | +12.6K shares |
| 3 years | +181586% | +12.7K shares |
RNAZ has 12,718 diluted shares, up 14862% from a year ago.
RNAZ Net Leverage
RNAZ's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
RNAZ Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 28.8 | Oversold |
| Stochastic | 1.9 | Oversold |
RNAZ's weekly RSI is 29 (oversold) and its Stochastic is 2 (oversold).
RNAZ PE vs Healthcare Sector
RNAZ has no meaningful PE right now: it lost money over the past year.
RNAZ Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.64 | 15% below |
| 20 week MA | $3.36 | 59% below |
| 50 week MA | $6.12 | 77% below |
| 100 week MA | $19.7 | 93% below |
| 200 week MA | $25,683.4 | 100% below |
RNAZ is in a downtrend: it's below all five of its weekly moving averages, and 100% below its 200-week average.
RNAZ Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $2,735,040.0 | $1,389,696.0 | -49% |
| 2022 | $1,389,696.0 | $187,002.8 | -87% |
| 2023 | $187,002.8 | $4,264.8 | -98% |
| 2024 | $4,264.8 | $72.0 | -98% |
| 2025 | $72.0 | $6.96 | -90% |
| 2026 YTD | $6.96 | $1.39 | -80% |
RNAZ has finished every year since 2021 lower, and it's down 80% so far in 2026.